Claims

1. A plasmid combination, wherein the plasmid combination comprises plasmids Seq1, PMD2.G, pMDLg-pRRE and pRSV-Rev; and the plasmids Seq1, PMD2.G, pMDLg-pRRE and pRSV-Rev are present at a ratio of 2-6: 1-1.5: 1-3: 1-1.5;
wherein the plasmid Seq1 comprises a nucleic acid molecule encoding a chimeric antigen receptor, wherein the chimeric antigen receptor comprises an amino acid sequence shown in SEQ ID NO. 1.

2. The plasmid combination according to claim 1, wherein the plasmid Seq1 comprises a nucleic acid molecule encoding a chimeric antigen receptor, wherein the nucleic acid molecule comprises a nucleic acid sequence shown in SEQ ID NO. 2.

3. A plasmid combination, wherein the plasmid combination comprises plasmids Seq1, PMD2.G, pMDLg-pRRE and pRSV-Rev; and the plasmids Seq1, PMD2.G, pMDLg-pRRE and pRSV-Rev are present at a ratio of 11.8: 3.53: 6.33: 2.3, 13.8: 3.48: 5.31: 2.54 or 14: 4.67: 4.67: 4.67;
wherein the plasmid Seq1 comprises a nucleic acid molecule encoding a chimeric antigen receptor, wherein the chimeric antigen receptor comprises an amino acid sequence shown in SEQ ID NO. 1.

4. A method for preparing a lentiviral vector, the method comprising introducing the plasmid combination according to any of claims 1 to 3 into a cell.

5. The method according to claim 4, wherein the cell is 293T.

6. A method for preparing a modified immune effector cell, comprising the following steps:

preparing the lentiviral vector according to the method according to either of claims 4-5; and

introducing the lentiviral vector into an immune effector cell.

7. The method according to claim 6, wherein the immune effector cell is selected from the group consisting of a T lymphocyte and a natural killer cell.